logo
Music Strikes a Chord for Brain Health

Music Strikes a Chord for Brain Health

Medscapea day ago

Music's influence on the brain is documented in conditions ranging from dementia, to epilepsy. Both music participation and appreciation are tied to improvements in executive function and memory so how close are we to harnessing music as a targeted therapeutic tool.
One researcher at the forefront of this work is Edward Large, PhD, a professor at the University of Connecticut in Storrs, Connecticut, and director of its Music Dynamics Laboratory. He told Medscape Medical News that he is optimistic about research suggesting that music can help, 'not just with depression and anxiety but with more profound neurological and psychological disorders.'
However, he added that music's benefits aren't yet fully understood. Robert Zatorre, PhD, founding co-director of the International Laboratory for Brain, Music, and Sound Research in Montreal, Quebec, Canada, cautions against overstating its therapeutic power.
'Music is not a magic pill; it's not a panacea; it doesn't cure everything,' said Zatorre who is also a professor at the Montreal Neurological Institute at McGill University, Montreal, Quebec, Canada.
Instead, it's important to define under what circumstances music could be beneficial and in what ways. 'And that's where the research is right now' he said.
Robert Zatorre, PhD
One challenge is music's deeply personal nature — what resonates with one person may leave another unmoved. Variables such as culture, age, personal history, social context, and even the nature of the neurological condition can influence how someone will respond to music-based interventions, said Zatorre.
Brain Rhythms and Memory
Large, a former president of the Society for Music Perception and Cognition and a musician himself, believes that one of the most important messages from research is the effect that music has on the rhythm of the brain.
Brain rhythms or waves, also known as neural oscillations, are patterns of brain activity associated with various cognitive processes and behaviors. In healthy brains, slow theta waves (4-8 Hz) and fast gamma waves (30-100 Hz) work together (coupling) to encode and retrieve new memories. Alzheimer's disease (AD) is characterized by disruptions in gamma waves and atypical cross-frequency coupling.
Edward Large, PhD
'Music is really the most powerful stimulus we have for synchronizing brain rhythms,' said Large.
His group is testing whether stimulating synchrony in the gamma frequency can help treat AD. 'That's the frequency at which neurons in the hippocampus synchronize when they're retrieving a memory', he said. Noninvasive, gamma-frequency, auditory-visual stimulation has been shown to improve AD-related biomarkers and memory in animal models.
Large is CEO of Oscillo Biosciences which is developing music based interventions for humans.
He explained how such interventions might work: The individual listens to self-selected music and watches a rhythmic light stimulus that is synchronized to the music as their brain waves are monitored via electroencephalography. The light show works in concert with the music to stimulate theta and gamma neural rhythms and phase-amplitude coupling (See photo).
It takes both the music and the synchronized light to have a similar effect to that seen for transcranial alternating-current stimulation, he said.
An early test of Oscillo Biosciences' music-based intervention for AD
Parkinson's Disease (PD)
In addition to its potential memory boosting, music can help improve motor control.
A music app was shown to improve gait and mood in patients with PD.
Daniel J. Levitin, PhD, a neuroscientist and professor emeritus of psychology at McGill University noted in a recent interview with CBC Radio, that music's steady beat can act as 'an external timekeeper' for patients with PD, helping them to walk better because of the auditory stimulation. For multiple sclerosis (MS), Levitin said that music can activate non-demyelinated circuits in order to help with motor control.
He echoed Zatorre's view that while the idea of a music prescription is appealing, what works best for a patient seems to be highly individualized.
'It's not like there is a single healing song or a list of healing songs,' he said in the interview. Instead, brain scans show that different types of songs can produce 'almost identical' brain activity in the limbic system, which is closely involved in experiencing pleasure, Levitin added.
The Pleasure Principle
The pleasure that music brings may be the source of its positive effects.
'I'm convinced that a lot of the benefits of these musical interventions act via the reward system,' said Zatorre who has conducted several related studies and authored a chapter on ' Musical Enjoyment and the Reward Circuits of the Brain ' for a book on Music and Mind edited by opera singer Renée Fleming.
By engaging the reward system 'it has knock-on effects on a lot of behaviors and cognitions, including social cognition and memory and language,' he said.
Zatorre theorized that music heard by a patient with a memory disorder will activate the reward pathway and simultaneously enhance the retrieval of certain memories. 'That's something that has been observed anecdotally in many patients with neurodegenerative disorders,' he said.
There is evidence that the connectivity of the auditory and reward systems is preserved in people with mild cognitive impairment and early AD opening up a potential pathway for early treatment. 'I'm not sure we're there yet. But it's something that people are excited about,' said Zatorre.
Familiar music tends to elicit a greater neural response, especially in older people, because once we reach a certain age, we know what we like and sticking to that brings enjoyment, which is linked to dopamine, explained Zatorre.
The reward system is highly reactive in younger people. 'We not only fall in love with people [more easily] at that age, we fall in love with all sorts of things and places and movies and music. And that tends to stay with us,' Zatorre said.
Large is currently conducting a functional MRI study in patients with AD that compares music that is self-selected and 'meaningful' to the participants with music that is merely familiar.
The meaningful music activates important parts of the brain such as the auditory cortex, hippocampus, and reward centers more than the familiar music, he reported. 'So if you're trying to have an impact on your brain, I think you should listen to the music that you love.'
Sing Like There's Nobody Listening?
A number of recent studies have suggested that physically participating in music may be even better for the brain than passively listening (Figure).
In a large nested study published last year, playing a musical instrument was linked to better executive function in older adults, with stronger links for woodwind instruments.
Keyboard playing was associated with better working memory compared to not playing any instrument. This study did not show any significant associations between listening to music and cognitive performance but singing was associated with better executive function.
Group singing may be particularly beneficial. A Finnish study tied singing in a choir to enhanced brain-structure connectivity across the lifespan of participants with no neurologic diagnoses at baseline.
Another recent study in 50 patients with chronic aphasia after stroke found that those assigned to participate in weekly sessions of group singing had improved communication and responsive speech production 5 months later compared to those who received standard of care.
'It has to do with the vocal motor control, the ability to control your larynx and your breathing and your articulators, as well as the vocalization that singing requires as opposed to speaking,' said Zatorre, who was not involved with the research.
He added that the social aspect of the intervention is also important, especially the 'singing together with other people who are suffering the same difficulties as you.'
Hope for the Tone Deaf
But what about people with congenital amusia ie, the tone deaf? Zatorre noted that about 50% of people who are tone deaf have perfect rhythm. 'They may not have the pitch correct, but they still are on time. So they can clap, or tap, or march, or dance, along to the beat,' he said.
While many may think they are tone deaf, it's estimated that only 1.5%of the general population have true congenital amusia and even fewer also have no rhythm. 'They may not enjoy the music itself but could enjoy the more social aspects of it. It's enjoying bonding with others, even if you're singing off-key,' said Zatorre.
He pointed out that patients with aphasia usually don't sing very well, 'but that's not the point.' Instead, the goal is improved outcome, he added. As the saying goes 'sing like there's nobody listening.'
Music As Preventive Medicine?
Could music be used as a preventive intervention to stave off, say, dementia in younger at-risk individuals?
'I think the answer is [that] we don't really know,' Large said. Although there are still questions about whether amyloid beta (Aβ) plaques are a cause or a symptom of AD, it's been shown that there is a desynchrony of rhythms in the gamma frequency band before a buildup of Aβ plaques occurs, he explained.
'I think that offers some hope that these rhythm-based therapies might have a preventive impact,' said Large.
Zatorre acknowledged that research on music as a preventive intervention is 'quite scarce,' but noted that adding music can still improve quality of life.
'Music is an important art form that almost all people are sensitive to. If you're having a better quality of life, that will enhance everything. Even if it doesn't prevent the formation of plaques in your brain, you will still have a happier existence. And then if you do develop any type of degenerative disorder, you'll have more tools in your toolbox to help you cope,' he said.
However, Zatorre noted that the same could be said for cooking or exercise or anything else that gives pleasure to an individual.
'I worry that music may have been a bit oversold to people, especially from those who are promoting a website or some type of self-help product. So I think caution is in order,' he said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

A woman's heart suddenly stopped. Two passing nurses saved her life.
A woman's heart suddenly stopped. Two passing nurses saved her life.

CBS News

time37 minutes ago

  • CBS News

A woman's heart suddenly stopped. Two passing nurses saved her life.

Merryl Hoffman knew she was taking good care of her heart. The 63-year-old attorney didn't smoke or drink, and she was an avid hiker who used to run marathons and other distance races. In her 40s, she had been diagnosed with a leaky mitral valve and underwent surgery to repair it. Every year since, she has seen a cardiologist to check her heart and its function. The reports always came back clear. When Hoffman left her apartment on Manhattan's Upper East Side on Oct. 23, 2025, her heart was the last thing on her mind. She was saddled with her work bag and purse, hightailing it to the subway station so she could make it to work on time. That's when her memory of the day ends. Shortly into her walk, Hoffman experienced a sudden cardiac arrest. Her heart stopped beating. She collapsed to the ground. Doctors later told her it was a severe arrhythmia that could have been fatal — if not for where Hoffman fell. Hoffman had collapsed outside Memorial Sloan Kettering Cancer Center's Breast and Imaging Center, about two and a half blocks from her subway station. A patient care technician and a passing runner immediately rushed to her aid. Then, Memorial Sloan Kettering nurses Sabrina Castle and Gianna Formisano stumbled upon the scene while walking to work. "We were so shocked. When we were walking up, people were like 'Nurses, nurses!' We didn't know what we were walking into," Formisano said. "People were grabbing our coffee, taking our bags. It was out of a movie, the way that they were like 'Oh, thank God you're here.'" Sabrina Castle and Gianna Formisano outside the Memorial Sloan Kettering Cancer Center. Memorial Sloan Kettering "They absolutely saved my life" Formisano and Castle took over performing CPR, keeping Hoffman's heart manually beating. She didn't have a pulse, and she had hit her head when she collapsed. The nurses also instructed one of the other bystanders to call an ambulance. Early CPR increases survival for patients in cardiac arrest by "at least two or three fold," said Dr. Jessica Hennessey, a cardiologist at NewYork-Presbyterian/Columbia University Irving Medical Center. Early CPR means that blood flow to the brain and heart continues, preserving the health of those organs. Bystanders in a medical emergency should call 911 and immediately start CPR, Hennessey advised. CPR can be done with mouth-to-mouth or with just chest compressions, Hennessey said. After five minutes that "felt like forever," the ambulance arrived, Formisano said. Castle and Formisano helped the EMTs load Hoffman into the ambulance. Then, she was taken to NewYork-Presbyterian's cardiac care unit for further treatment. For the small crowd, the day carried on. Castle and Formisano headed to work. After a few hours, they called NewYork-Presbyterian to see if they could find out more about Hoffman's status. They went to the hospital and spoke to a nurse there. "She was like, 'You got her back. She's intubated, she's alive, you saved her life,'" Castle recalled. Hoffman was still unconscious. She told CBS News that she didn't wake up until five days after the collapse. Her family told her that she had been rushed into surgery. Doctors told her that her heart had stopped for several minutes -- and the actions of Castle, Formisano and other bystanders had saved her. "Without them, I was told, there was no doubt I would have died or been brain dead," Hoffman said. "They absolutely saved my life." Hoffman had an implantable cardioverter-defibrillator placed in her chest to prevent further cardiac arrests. The device shocks the heart if it detects an irregular heartbeat. She also began cardiac rehabilitation. Shortly after, she returned to work. Life began to get back to normal but one question was constantly at the back of her mind: Who had helped save her? A chance reunion While in cardiac rehabilitation, Hoffman found herself telling the story of the strangers who had helped her. A physiologist there overheard her talking about it and thought the story sounded familiar. His girlfriend was friends with two nurses who had helped a woman matching Hoffman's description. After some back and forth, the physiologist connected Hoffman with Castle and Formisano. The trio immediately made plans to get dinner. Hoffman's husband joined them for the meal. There, the nurses were able to fill in the gaps of the October morning when Hoffman collapsed. Sabrina Castle, Merryl Hoffman and Gianna Formisano at the site where Hoffman collapsed. Sabrina Castle and Gianna Formisano "It was very jarring, when they gave my husband and I the blow-by-blow of that morning. There were things we did not know," Hoffman said. "It was pretty incredible." Since that dinner, the women have stayed in touch. Recently, Castle and Formisano even passed Hoffman on the same block where she had collapsed. The three took a photo at the site. "We were like, 'Wow, this is really crazy,'" Formisano said. "'We're running into you on the same spot, on your way to work, on our way to work, but now you're alive and well and in a much different state than when we met you the first time.'"

Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30?
Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30?

Yahoo

timean hour ago

  • Yahoo

Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30?

Rocket Lab is gaining a reputation for reliability in the rocket launch and space systems market. The company is building on its capabilities and improving its relationships as a defense contractor. While this young sector shows a lot of great promise, the stock looks overvalued today. 10 stocks we like better than Rocket Lab › Space is the final frontier, and it is now turning into a burgeoning economy. Researchers estimate that the space economy is worth over $500 billion with heavy spending from governments around the world along with private-company partners, and that figure is expected to grow to around $1.8 trillion a year by 2035. This is a huge opportunity for start-ups, perhaps rivaled only by artificial intelligence (AI) over the next decade when it comes to both growth rates and size. One company that dominates (and actually built) the entire space market is SpaceX. It's privately held, but luckily, investors have other space economy stocks that are turning into promising businesses. Enter Rocket Lab (NASDAQ: RKLB), the space flight company increasingly competing with SpaceX and developing promising capabilities to grow its presence in this large market. The stock has begun to soar again and is trading at around $26 as of this writing. Should you buy while shares are still under $30? Rocket Lab began its journey in the space economy with its small Electron rocket. It has now begun to expand and vertically integrate various space economy segments. It just acquired a company called Geost for $275 million. Geost develops optical and infrared capabilities for satellites with a focus on selling to the U.S. government's national security satellites. Rocket Lab is used by the government to launch its payloads into space. Now, it will be helping to build and operate these payloads for customers. It keeps vertically integrating its launch and space systems, which gives it a competitive advantage over other companies that only offer one or the other (SpaceX is the only other vertically integrated player). Rocket Lab offers solar energy, radio systems, and software for companies sending missions operating in space. This is why its backlog was over $1 billion as of the end of last quarter. Electron launch missions will continue throughout 2025, hopefully building on the company's strong safety and reliability record. The next step for the company will be testing and launching its larger Neutron rocket for customers. Testing is underway for this rocket right now with a planned mission for a confidential customer sometime in 2026. Larger rockets mean larger payloads, which means more revenue per launch. It also will give the company more of an opportunity to sell its space systems on these launches. The Neutron is the key for Rocket Lab to take the next step in its capabilities as a space flight company and to grow its backlog and revenue. Defense contracts have been a huge part of Rocket Lab's business. It currently helps with Air Force missions and a hypersonic testing program called HASTE. It was recently added to the National Security Space Launch (NSSL) program for its Neutron rocket, another reason why this new rocket is so important for the company's future. A growing relationship with the U.S. government could not have come at a better time for Rocket Lab. The government is set on spending a ton of money on space solutions as the next frontier in national defense. For example, the proposed Golden Dome missile defense project for the U.S. would cost an estimated $175 billion over three years to build. The company would be a prime candidate to win subcontracts for this ambitious project. As the Neutron comes on line and Rocket Lab builds up its capabilities and reputation in the space economy, we should see its backlog climb higher. This is a key indicator for investors to watch. The current backlog will have around half of its revenue recognized over the next 12 months, and half in later periods. In order to grow revenue over the long term, the company will need to grow its backlog and win more contracts from government and commercial customers. There is a lot of potential with Rocket Lab's business, but it might all be priced into the stock (and more) right now. It has a market cap of $12.3 billion. Revenue was only $466 million over the last 12 months. The company has never generated a profit and continues to lose money. If the company is successful with its ambitions to build a vertically integrated space company, it will eventually generate billions of dollars in revenue -- perhaps tens of billions 15 to 20 years from now. However, that is a long way off, and the stock looks fully priced versus what the company can accomplish in the next few years. For this reason, the stock looks like one to avoid even with the price under $30. The business may be promising, but the market is getting ahead of itself with Rocket Lab at the moment. This is a high-risk stock to keep out of your portfolio right now. Before you buy stock in Rocket Lab, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Rocket Lab wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $668,538!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $869,841!* Now, it's worth noting Stock Advisor's total average return is 789% — a market-crushing outperformance compared to 172% for the S&P 500. Don't miss out on the latest top 10 list, available when you join . See the 10 stocks » *Stock Advisor returns as of June 2, 2025 Brett Schafer has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Rocket Lab USA. The Motley Fool has a disclosure policy. Rocket Lab Stock Is Soaring Again: Should You Buy It Under $30? was originally published by The Motley Fool

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer
ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

Yahoo

timean hour ago

  • Yahoo

ASCO Report of Pioneering Treatment of Lymphopenia with Significant Overall Survival Benefit in Advanced Pancreatic Cancer

While Epogen and Neupogen addresses anemia and neutropenia, no therapy has existed for the treatment of lymphopenia until ANKTIVA® –The Cancer BioShield. Landmark overall survival benefit (P-value 0.005, HR: 0.46 [0.26, 0.80]) observed in 3rd-6th line metastatic pancreatic cancer, correlated with reversal of lymphopenia. Patients with lower tumor burden and improved lymphocyte counts (ALC ≥1,000) had a median overall survival of 10.1 months, supporting earlier intervention in the disease course. CULVER CITY, Calif., June 03, 2025--(BUSINESS WIRE)--ImmunityBio, Inc. (NASDAQ: IBRX) today announced results presented at ASCO 2025 of the first known treatment for lymphopenia with ANKTIVA and CAR-NK therapy. This data supports that reversal of lymphopenia, a well-established root cause of early mortality in patients with cancer across all tumor types, correlates with significant improved survival. While anemia and neutropenia have long been addressed by agents like Epogen and Neupogen, no therapy has ever existed for lymphopenia—until now. ANKTIVA (nogapendekin alfa inbakicept-pmln), an IL-15 superagonist approved in April 2024 for BCG-unresponsive non-muscle- invasive bladder cancer carcinoma in situ with or without papillary disease, represents the first lymphocyte-stimulating agent (LSA) capable of expanding lymphocytes critical for immunogenic cell death, such as natural killer (NK) and T cells. These findings emphasize the need for a therapy to overcome treatment induced lymphopenia with higher mortality as presented at ASCO 2025 by several institutions (Abstract #8054, Satoskar et al. and Abstract #2663, Saleh et al.) In a single-arm QUILT-88 clinical trial of 86 participants with third-to-sixth-line metastatic pancreatic cancer with very high tumor burden (CA19-9 levels exceeding 34,000 IU/ml), for which no therapy currently exists, patients received ANKTIVA subcutaneously in combination with off-the-shelf, ex-vivo infusion of CAR-NK cells (PD-L1 t-haNK) and low dose immuno-modulating chemotherapy. This first reported study of treating lymphopenia demonstrated significant differences in median overall survival in subjects whose lymphopenia was reversed (Absolute Lymphocyte Count: ALC ≥ 1,000). In 67 out of 86 subjects, reversal of lymphopenia was achieved and median overall survival was significantly prolonged compared to those who remained in severe lymphopenia with P-value 0.005, HR: 0.46 (0.26, 0.80) in Figure 1. In subjects with lymphopenia rescue and a lower tumor burden (less than the median CA19-9 of 34,000 IU/mL), the median overall survival in these very advanced metastatic pancreatic cancer patients exceeded 10 months (Figure 2). These findings of improved survival in pancreatic cancer patients with lower tumor burden point to the potential of further prolonged overall survival in pancreatic cancer patients if treated in the first line or neoadjuvant stages of disease. Highlighting the importance of lymphopenia reversal, Oncologist published a peer-reviewed paper titled "Recurrent pancreatic cancer treated with N-803 and PD-L1 t-haNK followed by an EGFR-targeted nanocell drug conjugate," demonstrating that in a patient with 2nd line metastatic pancreatic cancer treated with the full Cancer BioShield platform—including ANKTIVA, CAR-NK cells (PD-L1 t-haNK), and antigen-targeting adenoviruses—remained in remission for over six years and maintains a high quality of life at the date of this release. The expanded access authorization announced yesterday enables patients across all solid tumor types who have exhausted first-line therapy including chemotherapy, radiation, or immunotherapy to receive Anktiva as a lymphocyte stimulating agent to protect the immune system from the lymphogenic adverse effects of current standards of care. The ASCO Annual Meeting 2025 materials from ImmunityBio can be found below: Association of lymphopenia rescue and CA19-9 levels with overall survival following IL-15 superagonist N-803 and PD-L1 t-haNK chemo-immunotherapy for 3rd line or greater metastatic pancreatic Text: Poster PDF: About the Cancer BioShield™ Platform The Cancer BioShield platform is a first-in-class immunotherapy strategy designed to restore immune competence by reversing lymphopenia—the loss of functional immune cells caused by cancer itself and by conventional treatments such as chemotherapy, radiation and immunotherapy. At its core is ANKTIVA® (nogapendekin alfa inbakicept-pmln), an IL-15 agonist approved for BCG-unresponsive non-muscle-invasive bladder cancer CIS with or without papillary disease, activates and proliferates natural killer (NK) cells and CD4+ and CD8+ T cells, restoring lymphocyte levels critical for immunosurveillance, immunogenic cell death, and long-term tumor control. The platform employs a multi-modal approach: In-vivo stimulation: Subcutaneous administration of ANKTIVA expands NK and T cells, boosting anti-tumor immunity. Ex-vivo targeted cytotoxicity: Off-the-shelf PD-L1 t-haNK CAR-NK cells are engineered to target and eliminate PD-L1–expressing tumor cells and immunosuppressive neutrophils (myeloid-derived suppressor cells), enhancing anti-tumor specificity and reducing immune evasion. Memory Cytokine-Enriched Natural Killer (M-ceNK) cell therapy: M-ceNK cells are developed via cytokine activation and expansion of autologous and allogeneic NK cells collected through apheresis, potentially providing long-term immune memory and sustained cytotoxic capacity. Together, these components offer a comprehensive, novel, immune-restoring therapeutic platform aimed at not only expanding effector immune cells but also overcoming tumor-mediated immune suppression to support long-term disease control. The platform's effectiveness can be tracked through universally utilized, simple complete blood count (CBC): increases in absolute lymphocyte count (ALC) reflect ANKTIVA's lymphocyte-stimulating activity, while reductions in the neutrophil-to-lymphocyte ratio (NLR) demonstrate PD-L1 t-haNK's immunosuppressive neutrophil targeting. Low ALC and high NLR levels are laboratory measurements that have been extensively reported as predictive biomarkers of poor prognosis with early mortality across all tumor types5,6. The data presented by ImmunityBio for the first time demonstrates that improving ALC and NLR correlates with significant enhanced overall survival and clinical benefit. About Lymphopenia and Absolute Lymphocyte Count (ALC) Lymphopenia—the loss of key immune cells such as NK, CD4+, and CD8+ T cells—is a common side effect of chemotherapy1, radiation2,3, and some immunotherapies4. Unlike anemia and neutropenia, which have FDA-approved treatments like EPO and Neupogen, no therapy previously existed to treat this immune cell depletion. Lymphopenia weakens the immune system, increases infection risk, and is linked to early death across many cancer types5. Low Absolute Lymphocyte Count (ALC) is a recognized poor prognostic marker. ANKTIVA® is the first approved therapy to restore lymphocyte levels by activating and expanding NK and T cells—without increasing immunosuppressive T regulatory cells7. More information on lymphopenia could be found on Twitter/X @DrPatSoonShiong articles here: References: Ray-Coquard I, et al. Lymphopenia as a prognostic factor for overall survival in advanced carcinomas, sarcomas, and lymphomas. Cancer Res. 2009 Jul 1;69(13):5383-91. doi: 10.1158/ Epub 2009 Jun 23. PMID: 19549917; PMCID: PMC2775079. Chen D, et al. Absolute Lymphocyte Count Predicts Abscopal Responses and Outcomes in Patients Receiving Combined Immunotherapy and Radiation Therapy: Analysis of 3 Phase 1/2 Trials. Int J Radiat Oncol Biol Phys. 2020 Sep 1;108(1):196-203. doi: 10.1016/ Epub 2020 Feb 7. Pike LRG, et al. The Impact of Radiation Therapy on Lymphocyte Count and Survival in Metastatic Cancer Patients Receiving PD-1 Immune Checkpoint Inhibitors. Int J Radiat Oncol Biol Phys. 2019 Jan 1;103(1):142-151. doi: 10.1016/ Epub 2018 Sep 15. PMID: 30227198. Lee, Y.J., et al. Peripheral lymphocyte count as a surrogate marker of immune checkpoint inhibitor therapy outcomes in patients with non-small-cell lung cancer. Sci Rep 12, 626 (2022). Ménétrier-Caux C., et al. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? J Immunother Cancer. 2019 Mar 28;7(1):85. doi: 10.1186/s40425-019-0549-5. PMID: 30922400; PMCID: PMC6437964. Templeton AJ, et al. Prognostic role of neutrophil-to-lymphocyte (NLR) ratio in solid tumors: a systematic review and meta-analysis. J Natl Cancer Inst. 2014 May 29;106(6):dju124. doi: 10.1093/jnci/dju124. PMID: 24875653. FDA ANKTIVA Label, April 2024 - About ImmunityBio ImmunityBio is a vertically-integrated biotechnology company developing next-generation therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. The Company's range of immunotherapy and cell therapy platforms, alone and together, act to drive and sustain an immune response with the goal of creating durable and safe protection against disease. Designated an FDA Breakthrough Therapy, ANKTIVA is the first FDA-approved immunotherapy for non-muscle invasive bladder cancer CIS that activates natural killer cells, T cells, and memory T cells for a long-duration response. The Company is applying its science and platforms to treating cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies that we believe sharply reduce or eliminate the need for standard high-dose chemotherapy. These platforms and their associated product candidates are designed to be more effective, accessible, and easily administered than current standards of care in oncology and infectious diseases. For more information, visit (Founder's Vision) and connect with us on X (Twitter), Facebook, LinkedIn, and Instagram. Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements regarding clinical trial data and potential results and implications to be drawn therefrom, the expectation that the EAP described herein will enable access to ANKTIVA for patients across all solid tumor types who have exhausted first-line therapy including chemo, radiation or immunotherapy, the RMAT designation as previously reported and potential results therefrom and regulatory submissions in connection therewith, the belief that ALC levels and NLR levels obtained from a CBC are predictors of clinical benefit and outcomes relating to overall survival, the belief that improving ALC levels and NLR levels correlates with enhanced overall survival and clinical benefit, the belief that reversal of lymphopenia correlates with improved survival, clinical trial and expanded access program enrollment, data and potential results to be drawn therefrom, anticipated components of ImmunityBio's Cancer BioShield platform, the development of therapeutics for cancer and infectious diseases, potential benefits to patients, potential treatment outcomes for patients, the described mechanism of action and results and contributions therefrom, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents for the prevention or reversal of lymphopenia, potential future uses and applications of ANKTIVA alone or in combination with other therapeutic agents across multiple tumor types and indications and for potential applications beyond oncology, potential regulatory pathways and the regulatory review process and timing thereof, the application of the Company's science and platforms to treat cancers or develop cancer vaccines, immunotherapies and cell therapies that has the potential to change the paradigm in cancer care, and ImmunityBio's approved product and investigational agents as compared to existing treatment options, among others. Statements in this press release that are not statements of historical fact are considered forward-looking statements, which are usually identified by the use of words such as "anticipates," "believes," "continues," "goal," "could," "estimates," "scheduled," "expects," "intends," "may," "plans," "potential," "predicts," "indicate," "projects," "is," "seeks," "should," "will," "strategy," and variations of such words or similar expressions. Statements of past performance, efforts, or results of our preclinical and clinical trials, about which inferences or assumptions may be made, can also be forward-looking statements and are not indicative of future performance or results. Forward-looking statements are neither forecasts, promises nor guarantees, and are based on the current beliefs of ImmunityBio's management as well as assumptions made by and information currently available to ImmunityBio. Such information may be limited or incomplete, and ImmunityBio's statements should not be read to indicate that it has conducted a thorough inquiry into, or review of, all potentially available relevant information. Such statements reflect the current views of ImmunityBio with respect to future events and are subject to known and unknown risks, including business, regulatory, economic and competitive risks, uncertainties, contingencies and assumptions about ImmunityBio, including, without limitation, (i) risks and uncertainties regarding the FDA regulatory submission, filing and review process and the timing thereof, (ii) whether the RMAT designation will lead to an accelerated review or approval, of which there can be no assurance, (iii) risks and uncertainties regarding commercial launch execution, success and timing, (iv) risks and uncertainties regarding participation and enrollment and potential results from the expanded access clinical investigation program described herein, (v) whether clinical trials will result in registrational pathways and the risks, (vi) whether clinical trial data will be accepted by regulatory agencies, (vii) the ability of ImmunityBio to continue its planned preclinical and clinical development of its development programs through itself and/or its investigators, and the timing and success of any such continued preclinical and clinical development, patient enrollment and planned regulatory submissions, (viii) potential delays in product availability and regulatory approvals, (ix) ImmunityBio's ability to retain and hire key personnel, (x) ImmunityBio's ability to obtain additional financing to fund its operations and complete the development and commercialization of its various product candidates, (xi) potential product shortages or manufacturing disruptions that may impact the availability and timing of product, (xii) ImmunityBio's ability to successfully commercialize its approved product and product candidates, (xiii) ImmunityBio's ability to scale its manufacturing and commercial supply operations for its approved product and future approved products, and (xiv) ImmunityBio's ability to obtain, maintain, protect, and enforce patent protection and other proprietary rights for its product candidates and technologies. More details about these and other risks that may impact ImmunityBio's business are described under the heading "Risk Factors" in the Company's Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 3, 2025, and the Company's Form 10-Q filed with the SEC on May 12, 2025, and in subsequent filings made by ImmunityBio with the SEC, which are available on the SEC's website at ImmunityBio cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date hereof. View source version on Contacts ImmunityBio Contacts: Investors Hemanth Ramaprakash, PhD, MBA ImmunityBio, Inc. +1 Media Sarah Singleton ImmunityBio, Inc. +1 Sign in to access your portfolio

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store